On April 8, 2021, Folmer, Rutger; Hekking, Koen F. W.; Calpe, Blaise; Mueller, Gerhard; Fabritius, Charles-Henry published a patent.SDS of cas: 50743-01-6 The title of the patent was Azaindole derivatives and related compounds as inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1B and their preparation. And the patent contained the following:
The invention relates to compounds of formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in particular for use in the treatment, amelioration or prevention of cancer, Alzheimer, Parkinson, Down syndrome, metabolic syndrome, diabetes and/or osteoarthritis. Compounds of formula I wherein X1 is N, CH and CF; X2 = N, CH and CR1; each R2 is independently H and R1; Y1 is S and O; Y2 is C, CN, CMe, CCl and CF; Y3 is N, CH and CR1; A is (un)substituted (mono/bi/tri)cyclic heterocyclyl; R1 is (un)substituted C1-6 alkyl, halo, CN, NO2, etc.; and pharmaceutically acceptable salts, solvates, cocrystals, tautomers, racemates, enantiomers, diastereomers and mixtures thereof, are claimed. Example compound II was prepared by cyclization of 2-chloro-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-one with 1H-imidazole-4-carbothioamide. The invention compounds were evaluated for their DYRK1B inhibitory activity. From the assay it was determined that compound II exhibited IC50 value in the range of 10 nM to < 100 nM. The experimental process involved the reaction of 5-Bromo-1H-imidazole-4-carbaldehyde(cas: 50743-01-6).SDS of cas: 50743-01-6
The Article related to azaindole preparation dyrk1b inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.SDS of cas: 50743-01-6
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem